Financials JCR Pharmaceuticals Co., Ltd.

Equities

4552

JP3701000006

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-05-21 am EDT 5-day change 1st Jan Change
619 JPY -2.67% Intraday chart for JCR Pharmaceuticals Co., Ltd. -3.28% -47.18%

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 200,747 290,393 443,148 279,312 176,306 79,374 - -
Enterprise Value (EV) 1 197,730 287,957 434,988 266,435 185,828 107,204 83,318 86,424
P/E ratio 54 x 108 x 64.2 x 19.2 x 46.6 x 19.5 x 12.3 x 12.9 x
Yield 0.46% 0.34% 0.33% 0.89% 1.42% 2.33% 3.14% 3.21%
Capitalization / Revenue 8.67 x 11.7 x 14.7 x 5.47 x 5.13 x 2.5 x 1.9 x 1.9 x
EV / Revenue 8.54 x 11.6 x 14.5 x 5.22 x 5.41 x 2.5 x 2 x 2.07 x
EV / EBITDA 31.3 x 61.6 x 42.8 x 12.2 x 26.7 x 7.4 x 8.42 x 8.3 x
EV / FCF 62.2 x 3,235 x 61.7 x 44.1 x -9.06 x -80.8 x 7.11 x 13.2 x
FCF Yield 1.61% 0.03% 1.62% 2.27% -11% -1.24% 14.1% 7.58%
Price to Book 6.64 x 9.13 x 11.7 x 5.55 x 3.43 x 1.94 x 1.3 x 1.19 x
Nbr of stocks (in thousands) 123,158 123,309 123,612 123,754 124,774 124,801 - -
Reference price 2 1,630 2,355 3,585 2,257 1,413 636.0 636.0 636.0
Announcement Date 5/10/19 5/12/20 5/13/21 5/12/22 5/11/23 5/10/24 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 23,160 24,781 30,085 51,082 34,343 42,871 41,752 41,771
EBITDA 1 6,310 4,678 10,161 21,878 6,972 12,432 9,901 10,418
EBIT 1 4,967 3,244 8,269 19,933 4,975 7,531 9,310 8,398
Operating Margin 21.45% 13.09% 27.49% 39.02% 14.49% 17.57% 22.3% 20.1%
Earnings before Tax (EBT) 1 4,928 3,422 8,653 19,404 5,412 7,244 7,374 7,720
Net income 1 3,715 2,678 6,892 14,507 3,772 5,507 5,901 6,153
Net margin 16.04% 10.81% 22.91% 28.4% 10.98% 12.85% 14.13% 14.73%
EPS 2 30.17 21.72 55.81 117.3 30.35 44.13 51.52 49.36
Free Cash Flow 1 3,177 89 7,051 6,039 -20,502 -1,139 11,723 6,553
FCF margin 13.72% 0.36% 23.44% 11.82% -59.7% -2.51% 28.08% 15.69%
FCF Conversion (EBITDA) 50.35% 1.9% 69.39% 27.6% - - 118.4% 62.9%
FCF Conversion (Net income) 85.52% 3.32% 102.31% 41.63% - - 198.67% 106.5%
Dividend per Share 2 7.500 8.000 12.00 20.00 20.00 20.00 20.00 20.43
Announcement Date 5/10/19 5/12/20 5/13/21 5/12/22 5/11/23 5/10/24 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2020 S1 2021 S1 2021 S2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 11,236 10,951 19,134 28,383 11,887 10,812 22,699 9,606 5,975 15,581 11,115 7,647 18,762 10,808 13,464 24,272 9,446 9,153 18,599 - - - -
EBITDA - - - - - - - - - - - - - - - - - - - - - - -
EBIT 1 998 1,307 6,962 13,640 4,716 1,577 6,293 1,536 -792 744 4,209 22 4,231 2,066 4,832 6,898 911 -278 633 - - - -
Operating Margin 8.88% 11.93% 36.39% 48.06% 39.67% 14.59% 27.72% 15.99% -13.26% 4.78% 37.87% 0.29% 22.55% 19.12% 35.89% 28.42% 9.64% -3.04% 3.4% - - - -
Earnings before Tax (EBT) 1 1,098 1,381 7,272 12,729 4,993 1,682 6,675 2,083 - 1,560 3,720 132 3,852 2,260 - 7,120 251 -127 124 - - - -
Net income 1 922 1,227 5,665 9,234 3,687 1,586 5,273 1,368 -406 962 2,606 204 2,810 1,610 3,643 5,253 -93 347 254 - - - -
Net margin 8.21% 11.2% 29.61% 32.53% 31.02% 14.67% 23.23% 14.24% -6.79% 6.17% 23.45% 2.67% 14.98% 14.9% 27.06% 21.64% -0.98% 3.79% 1.37% - - - -
EPS 2 7.488 9.940 45.87 74.66 29.79 12.81 42.60 11.06 -3.290 7.770 20.96 1.620 22.58 12.91 29.19 42.10 -0.7500 2.780 - - - - -
Dividend per Share 2 3.750 4.500 - 10.00 - - - - - 10.00 - - - - - 10.00 - 10.00 - 10.00 - 10.00 -
Announcement Date 10/31/19 10/26/20 5/13/21 10/28/21 1/27/22 5/12/22 5/12/22 7/27/22 10/26/22 10/26/22 1/31/23 5/11/23 5/11/23 7/26/23 10/25/23 10/25/23 1/26/24 5/10/24 5/10/24 - - - -
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - 9,522 12,659 3,944 7,051
Net Cash position 1 3,017 2,436 8,160 12,877 - - - -
Leverage (Debt/EBITDA) - - - - 1.366 x 1.018 x 0.3983 x 0.6768 x
Free Cash Flow 1 3,177 89 7,051 6,039 -20,502 -1,139 11,723 6,553
ROE (net income / shareholders' equity) 13% 8.6% 19.5% 32.9% 7.4% 10.3% 9.95% 9.65%
ROA (Net income/ Total Assets) 12.5% 7.29% 14.2% 24% 5.64% 7.37% 5.27% 3.55%
Assets 1 29,656 36,714 48,585 60,440 66,860 74,737 112,041 173,328
Book Value Per Share 2 246.0 258.0 306.0 407.0 412.0 444.0 491.0 535.0
Cash Flow per Share 2 41.10 33.40 71.10 133.0 46.40 69.80 60.40 59.90
Capex 1 728 4,838 4,780 11,333 8,023 5,250 3,000 2,750
Capex / Sales 3.14% 19.52% 15.89% 22.19% 23.36% 11.57% 7.19% 6.58%
Announcement Date 5/10/19 5/12/20 5/13/21 5/12/22 5/11/23 5/10/24 - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
636 JPY
Average target price
1,557 JPY
Spread / Average Target
+144.83%
Consensus
  1. Stock Market
  2. Equities
  3. 4552 Stock
  4. Financials JCR Pharmaceuticals Co., Ltd.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW